Spots Global Cancer Trial Database for imprime pgg
Every month we try and update this database with for imprime pgg cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer | NCT00874848 | NSCLC | Imprime PGG Inj... Cetuximab Paclitaxel Carboplatin | 18 Years - 75 Years | HiberCell, Inc. | |
| Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma | NCT04995094 | Pathologic Stag... | Imprime PGG Pembrolizumab | 18 Years - | HiberCell, Inc. | |
| A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC) | NCT03555149 | Colorectal Canc... | Regorafenib Atezolizumab Imprime PGG Bevacizumab Isatuximab Selicrelumab Idasanutlin AB928 LOAd703 | 18 Years - | Hoffmann-La Roche | |
| Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer | NCT02981303 | Advanced Melano... Triple-Negative... | Imprime PGG Pembrolizumab | 18 Years - | HiberCell, Inc. | |
| Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer | NCT01309126 | Colorectal Canc... | Imprime PGG + c... Cetuximab | 18 Years - | HiberCell, Inc. | |
| Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia | NCT01269385 | B-cell Chronic ... Refractory Chro... Stage 0 Chronic... Stage I Chronic... Stage II Chroni... | alemtuzumab rituximab PGG beta-glucan flow cytometry laboratory biom... DNA analysis fluorescence in... polymerase chai... polymorphism an... mutation analys... | 18 Years - | Mayo Clinic | |
| Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA) | NCT05159778 | Malignant Neopl... | Imprime PGG Pembrolizumab | 18 Years - | HiberCell, Inc. | |
| (PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer | NCT02132403 | Pancreatic Canc... | BTH1704 IMPRIME PGG Gemcitabine | 18 Years - | University of Illinois at Chicago | |
| Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer | NCT01309126 | Colorectal Canc... | Imprime PGG + c... Cetuximab | 18 Years - | HiberCell, Inc. | |
| A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC) | NCT03555149 | Colorectal Canc... | Regorafenib Atezolizumab Imprime PGG Bevacizumab Isatuximab Selicrelumab Idasanutlin AB928 LOAd703 | 18 Years - | Hoffmann-La Roche | |
| Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD | NCT03246685 | Squamous Cell C... | Imprime PGG Pembrolizumab | 18 Years - | HiberCell, Inc. | |
| Efficacy and Safety Study of Imprime PGG With Cetuximab in Subjects With Stage IV KRAS-Mutated Colorectal Cancer | NCT00912327 | Colorectal Canc... | Imprime PGG | 18 Years - | HiberCell, Inc. | |
| (PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer | NCT02132403 | Pancreatic Canc... | BTH1704 IMPRIME PGG Gemcitabine | 18 Years - | University of Illinois at Chicago | |
| Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC) | NCT00874107 | Non-Small Cell ... | Imprime PGG® In... Bevacizumab Paclitaxel Carboplatin | 18 Years - 75 Years | HiberCell, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
